Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease
Abstract Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the Alzheimer’s disease (AD) continuum. Investigating populations with SCD is important for understanding the early pathological mechanisms of AD and identifying SCD-related biomarkers, which are critical...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-09-01
|
| Series: | Molecular Neurodegeneration |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13024-020-00395-3 |
| _version_ | 1818047983184248832 |
|---|---|
| author | Xiaoqi Wang Weijie Huang Li Su Yue Xing Frank Jessen Yu Sun Ni Shu Ying Han |
| author_facet | Xiaoqi Wang Weijie Huang Li Su Yue Xing Frank Jessen Yu Sun Ni Shu Ying Han |
| author_sort | Xiaoqi Wang |
| collection | DOAJ |
| description | Abstract Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the Alzheimer’s disease (AD) continuum. Investigating populations with SCD is important for understanding the early pathological mechanisms of AD and identifying SCD-related biomarkers, which are critical for the early detection of AD. With the advent of advanced neuroimaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), accumulating evidence has revealed structural and functional brain alterations related to the symptoms of SCD. In this review, we summarize the main imaging features and key findings regarding SCD related to AD, from local and regional data to connectivity-based imaging measures, with the aim of delineating a multimodal imaging signature of SCD due to AD. Additionally, the interaction of SCD with other risk factors for dementia due to AD, such as age and the Apolipoprotein E (ApoE) ɛ4 status, has also been described. Finally, the possible explanations for the inconsistent and heterogeneous neuroimaging findings observed in individuals with SCD are discussed, along with future directions. Overall, the literature reveals a preferential vulnerability of AD signature regions in SCD in the context of AD, supporting the notion that individuals with SCD share a similar pattern of brain alterations with patients with mild cognitive impairment (MCI) and dementia due to AD. We conclude that these neuroimaging techniques, particularly multimodal neuroimaging techniques, have great potential for identifying the underlying pathological alterations associated with SCD. More longitudinal studies with larger sample sizes combined with more advanced imaging modeling approaches such as artificial intelligence are still warranted to establish their clinical utility. |
| first_indexed | 2024-12-10T10:14:27Z |
| format | Article |
| id | doaj.art-f40ff66c20da4d0c80708c1e6580b940 |
| institution | Directory Open Access Journal |
| issn | 1750-1326 |
| language | English |
| last_indexed | 2024-12-10T10:14:27Z |
| publishDate | 2020-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Neurodegeneration |
| spelling | doaj.art-f40ff66c20da4d0c80708c1e6580b9402022-12-22T01:53:02ZengBMCMolecular Neurodegeneration1750-13262020-09-0115112710.1186/s13024-020-00395-3Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s diseaseXiaoqi Wang0Weijie Huang1Li Su2Yue Xing3Frank Jessen4Yu Sun5Ni Shu6Ying Han7Department of Neurology, Xuanwu Hospital of Capital Medical UniversityState Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal UniversityDepartment of Psychiatry, University of CambridgeRadiological Sciences, Division of Clinical Neuroscience, University of NottinghamDepartment of Psychiatry and Psychotherapy, Medical Faculty, University of CologneDepartment of Neurology, Xuanwu Hospital of Capital Medical UniversityState Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal UniversityDepartment of Neurology, Xuanwu Hospital of Capital Medical UniversityAbstract Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the Alzheimer’s disease (AD) continuum. Investigating populations with SCD is important for understanding the early pathological mechanisms of AD and identifying SCD-related biomarkers, which are critical for the early detection of AD. With the advent of advanced neuroimaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), accumulating evidence has revealed structural and functional brain alterations related to the symptoms of SCD. In this review, we summarize the main imaging features and key findings regarding SCD related to AD, from local and regional data to connectivity-based imaging measures, with the aim of delineating a multimodal imaging signature of SCD due to AD. Additionally, the interaction of SCD with other risk factors for dementia due to AD, such as age and the Apolipoprotein E (ApoE) ɛ4 status, has also been described. Finally, the possible explanations for the inconsistent and heterogeneous neuroimaging findings observed in individuals with SCD are discussed, along with future directions. Overall, the literature reveals a preferential vulnerability of AD signature regions in SCD in the context of AD, supporting the notion that individuals with SCD share a similar pattern of brain alterations with patients with mild cognitive impairment (MCI) and dementia due to AD. We conclude that these neuroimaging techniques, particularly multimodal neuroimaging techniques, have great potential for identifying the underlying pathological alterations associated with SCD. More longitudinal studies with larger sample sizes combined with more advanced imaging modeling approaches such as artificial intelligence are still warranted to establish their clinical utility.http://link.springer.com/article/10.1186/s13024-020-00395-3subjective cognitive declineAlzheimer’s diseaseneuroimagingmultimodal MRIPET |
| spellingShingle | Xiaoqi Wang Weijie Huang Li Su Yue Xing Frank Jessen Yu Sun Ni Shu Ying Han Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease Molecular Neurodegeneration subjective cognitive decline Alzheimer’s disease neuroimaging multimodal MRI PET |
| title | Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease |
| title_full | Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease |
| title_fullStr | Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease |
| title_full_unstemmed | Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease |
| title_short | Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease |
| title_sort | neuroimaging advances regarding subjective cognitive decline in preclinical alzheimer s disease |
| topic | subjective cognitive decline Alzheimer’s disease neuroimaging multimodal MRI PET |
| url | http://link.springer.com/article/10.1186/s13024-020-00395-3 |
| work_keys_str_mv | AT xiaoqiwang neuroimagingadvancesregardingsubjectivecognitivedeclineinpreclinicalalzheimersdisease AT weijiehuang neuroimagingadvancesregardingsubjectivecognitivedeclineinpreclinicalalzheimersdisease AT lisu neuroimagingadvancesregardingsubjectivecognitivedeclineinpreclinicalalzheimersdisease AT yuexing neuroimagingadvancesregardingsubjectivecognitivedeclineinpreclinicalalzheimersdisease AT frankjessen neuroimagingadvancesregardingsubjectivecognitivedeclineinpreclinicalalzheimersdisease AT yusun neuroimagingadvancesregardingsubjectivecognitivedeclineinpreclinicalalzheimersdisease AT nishu neuroimagingadvancesregardingsubjectivecognitivedeclineinpreclinicalalzheimersdisease AT yinghan neuroimagingadvancesregardingsubjectivecognitivedeclineinpreclinicalalzheimersdisease |